Insmed Inc

1INSM

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,664

Stocks News & Analysis

stocks

Chart of the Week: Has gold reached bear market territory?

Investors are facing a shifting landscape.
stocks

ASX share benefiting from favourable industry trends

We anticipate further earnings growth.
stocks

Fair value upgrade for this ASX income player

Headwinds in listed energy stocks likely to have passed

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,885.6059.900.68%
CAC 407,974.82157.882.02%
DAX 4023,287.09607.052.68%
Dow JONES (US)46,691.871,475.733.26%
FTSE 10010,345.53169.081.66%
HKSE25,294.03505.892.04%
NASDAQ21,847.181,052.545.06%
Nikkei 22553,739.682,675.965.24%
NZX 50 Index12,825.8786.24-0.67%
S&P 5006,581.0052.480.80%
S&P/ASX 2008,671.8053.100.62%
SSE Composite Index3,948.5556.691.46%

Market Movers